Literature DB >> 427687

Porphyria cutanea tarda: clinical and laboratory features.

G D Sweeney, K G Jones.   

Abstract

Eleven patients with porphyria cutanea tarda were studied. Biochemical confirmation of the clinical diagnosis required only determination of the total urine porphyrin concentration in a sample of urine voided on rising in the morning. The patients were divided for convenience of discussion into four groups differing in age, sex and etiologic factors. Of the six patients in whom a liver biopsy was done one was shown to have micronodular cirrhosis. Except for a modest elevation in the serum glutamic oxaloacetic transaminase values when the patients were first seen, no evidence was found for liver disease apart from the presence of porphyria cutanea tarda. One patient recovered solely by abstaining from alcohol consumption. Five patients underwent phlebotomy; their iron stores had been found to be between 2 and 3 g. Decreasing urine porphyrin values correlated well with decreasing serum ferritin values during the course of phlebotomy. Porphyria cutanea tarda, which is due to a deficiency of uroporphyrinogen decarboxylase, is manifested in association with alcohol abuse, estrogen therapy, exposure to chlorinated hydrocarbons or increased tissue iron stores, or a combination of these factors. Although relatively uncommon, this condition raises important and unresolved issues regarding the hepatotoxicity of alcohol, estrogens, chlorinated hydrocarbons and iron.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 427687      PMCID: PMC1818968     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  16 in total

1.  Measurement of urine porphyrins and porphyrinogens.

Authors:  K G Jones; G D Sweeney
Journal:  Biochem Med       Date:  1976-06

2.  INDUSTRIALLY ACQUIRED PORPHYRIA.

Authors:  J BLEIBERG; M WALLEN; R BRODKIN; I L APPLEBAUM
Journal:  Arch Dermatol       Date:  1964-06

3.  Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide.

Authors:  C CAN; G NIGOGOSYAN
Journal:  JAMA       Date:  1963-01-12       Impact factor: 56.272

4.  EFFECTS OF CHLOROQUINE ON PATIENTS WITH CUTANEOUS PORPHYRIA OF THE "SYMPTOMATIC" TYPE.

Authors:  G D SWEENEY; S J SAUNDERS; E B DOWDLE; L EALES
Journal:  Br Med J       Date:  1965-05-15

5.  PATTERNS OF PORPHYRIN EXCRETION IN SOUTH AFRICA PORPHYRIC PATIENTS.

Authors:  G D SWEENEY
Journal:  S Afr J Lab Clin Med       Date:  1963-12

6.  Porphyrin content of bone marrow and liver in the various forms of porphyria.

Authors:  R SCHMID; S SCHWARTZ; C J WATSON
Journal:  AMA Arch Intern Med       Date:  1954-02

7.  Iron metabolism; iron stores in man as measured by phlebotomy.

Authors:  D HASKINS; A R STEVENS; S FINCH; C A FINCH
Journal:  J Clin Invest       Date:  1952-06       Impact factor: 14.808

8.  Porphyria cutanea tarda in three generations of a single family.

Authors:  A V Benedetto; J P Kushner; J S Taylor
Journal:  N Engl J Med       Date:  1978-02-16       Impact factor: 91.245

9.  Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda.

Authors:  G H Elder; G B Lee; J A Tovey
Journal:  N Engl J Med       Date:  1978-08-10       Impact factor: 91.245

10.  A radioimmunoassay for serum ferritin.

Authors:  A W Luxton; W H Walker; J Gauldie; A M Ali; C Pelletier
Journal:  Clin Chem       Date:  1977       Impact factor: 8.327

View more
  2 in total

1.  Porphyria cutanea tarda due to ferrous gluconate.

Authors:  A D Ginsburg; L J Margesson; K Feleki
Journal:  CMAJ       Date:  1990-10-15       Impact factor: 8.262

2.  66-year-old woman with painless vesicular lesions.

Authors:  Aditya Bardia; Elizabeth A Swanson; Kris G Thomas
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.